Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503) 10903 New Hampshire Avenue, Silver Spring, Maryland July 13, 2017

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Jay R. Fajiculay, PharmD

Division of Advisory Committee and Consultant Management Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Grzegorz S. Nowakowski, MD

Associate Professor of Medicine and Oncology Mayo Clinic Rochester Rochester, Minnesota

Gregory J. Riely, MD, PhD

(morning session only)
Associate Attending Physician
Memorial Sloan-Kettering Cancer Center
Associate Professor
Weill Cornell Medical College
New York, New York

Bruce. J. Roth, MD

(Chairperson)
Professor of Medicine
Division of Oncology
Washington University School of Medicine
St. Louis, Missouri

Courtney J. Preusse, MA

(Consumer Representative)
Senior Research Administrator and CLIA
Operations Director
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Brian I. Rini, MD, FACP

(afternoon session only)
Professor of Medicine, Lerner College of Medicine
Leader, GU Program
Department of Hematology and Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Thomas S. Uldrick, MD, MS

Clinical Director HIV & AIDS Malignancy Branch Center for Cancer Research National Cancer Institute Bethesda, Maryland

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Gary Gordon, MD, PhD

Vice President, Oncology Development Abbvie North Chicago, Illinois

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting July 13, 2017

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Deborah K. Armstrong, MD

Professor of Oncology Johns Hopkins Kimmel Cancer Center Johns Hopkins University School of Medicine Professor of Gynecology and Obstetrics Johns Hopkins School of Medicine Baltimore, Maryland

Shein-Chung Chow, PhD

Professor, Biostatistics and Bioinformatics Duke University School of Medicine Durham, North Carolina

Craig W. Hendrix, MD

Wellcome Professor and Director
Division of Clinical Pharmacology
Departments of Medicine and Pharmacology and
Molecular Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Donald E. Mager, PharmD, PhD

Professor of Pharmaceutical Sciences
Department of Pharmaceutical Sciences
School of Pharmacy and Pharmaceutical Sciences
University of Buffalo, State University of
New York
Buffalo, New York

Diane Reidy-Lagunes, MD

(morning session only)
Associate Deputy Physician in Chief of Clinical Operations
Memorial Sloan-Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Cynthia Chauhan

(Patient Representative) Wichita, Kansas

Bernard F. Cole, PhD

Professor Department of Mathematics and Statistics University of Vermont Burlington, Vermont

Adel H. Karara, PhD, FCP

Professor of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Princess Anne, Maryland

Antonio R. Moreira, PhD

Vice Provost for Academic Affairs Professor of Chemical, Biochemical and Environmental Engineering University of Maryland, Baltimore County Baltimore, Maryland

John E. Schiel, PhD

Research Chemist Institute for Bioscience and Biotechnology Research National Institute of Standards and Technology Rockville, Maryland

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting July 13, 2017

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Deborah Schrag, MD, MPH

(morning session only)
Chief, Population Sciences
Dana Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Andrew D. Seidman, MD

(afternoon session only)
Attending Physician
Breast Medicine Service
Associate Chair, Academic Administration
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Scott A. Waldman, MD, PhD, FCP, FAHA

Director, Gastrointestinal Cancer Program of the Sidney Kimmel Cancer Center Samuel M.V. Hamilton Professor of Medicine Chair, Department of Pharmacology and Experimental Therapeutics Thomas Jefferson University Philadelphia, Pennsylvania

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting July 13, 2017

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

(afternoon session only)
Director, Oncology Center of Excellence, FDA
Acting Director, Office of Hematology &
Oncology
Products (OHOP), OND, CDER, FDA

Patricia Keegan, MD

(morning session only)
Director
Division of Oncology Products 2 (DOP2)
OHOP, OND, CDER, FDA

Steven Kozlowski, MD

Director Office of Biotechnology Products (OBP) Office of Pharmaceutical Quality (OPQ) CDER, FDA

Laleh Amiri-Kordestani, MD

(afternoon session only)
Clinical Team Leader
Breast Cancer Team
DOP1, OHOP, OND, CDER, FDA

Leah Christl, PhD

Associate Director for Therapeutic Biologics OND Therapeutic Biologics and Biosimilars Staff (TBBS) OND, CDER, FDA

Julia Beaver, MD

(afternoon session only)
Acting Director
Division of Oncology Products 1 (DOP1)
OHOP, OND, CDER, FDA

Steven Lemery, MD

(morning session only)
Acting Associate Deputy Director
DOP2, OHOP, OND, CDER, FDA